Impact of screening on incidence and mortality of prostate cancer in the United States.
about
Gene expression profiling predicts clinical outcome of prostate cancerA Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside PotentialRecent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results ProgramCancer screening: the journey from epidemiology to policy.Symptomatic diagnosis of prostate cancer in primary care: a structured review.Long noncoding RNAs as putative biomarkers for prostate cancer detection.The Japanese guideline for prostate cancer screening.Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.Historical cancer incidence and mortality assessment in an Illinois community proximal to a former manufactured gas plant.Racial and geographic disparities in late-stage prostate cancer diagnosis in Florida.Screening for prostate cancer: have you had your cholesterol measured?The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening?The impact of place and time on the proportion of late-stage diagnosis: the case of prostate cancer in Florida, 1981-2007.Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.Expectant management: an option for localized prostate cancer.Prostate cancer survival in Trinidad: Is PSA a prognostic factor?Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up.National evidence on the use of shared decision making in prostate-specific antigen screening.Beyond PSA: the next generation of prostate cancer biomarkers.Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.Novel biomarkers for the detection of prostate cancer.Predictions for the future of kallikrein-related peptidases in molecular diagnostics.New concepts concerning prostate cancer screening.Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer.Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.Older Korean American men's prostate cancer screening behavior: the prime role of culture.Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015.The Use of Biomarkers in Prostate Cancer Screening and Treatment.Opportunities and outcomes in early prostate cancer: a commentary on policy, patient perspectives, trials and strategies.
P2860
Q24594253-F8C878D8-6159-4846-96BC-7DB7BF5B7E88Q27022638-0EE0310E-90A8-48A6-9DF4-63CBC84C1DA0Q33517492-002E22F4-CF75-4E55-ACDB-8900B8429BB0Q33897050-B20D72D5-DBE7-4022-8BA8-16F6F35D2181Q34247769-68D29742-A5DE-4829-90A6-86CD35E977A5Q34409743-931336EB-A1CD-4202-A5DB-5C78F77DDAD1Q34606240-B97FA1BF-7149-4616-A0A0-EDC493A7239EQ34624597-A31FCBE2-7AEF-4C16-AC3E-60E8DC61EF2DQ34767831-93258B9A-33E7-435E-8150-80AF16EAB7D8Q35111916-5295ED03-19BC-4BA6-B4EE-CAD7AE74267AQ35187517-FA6D6595-0E81-44F6-AF45-347DFDC3B69FQ35675439-8E5AC736-B791-4B45-9F66-176D0A829FC8Q36075025-5A33F77F-515E-48A1-BB91-AB0A78F488C0Q36093830-3761E763-5F6E-4E68-9DD0-E68EB93B6F60Q36244110-60366841-0B7A-44CD-BCA0-6BBF1002DC51Q36487174-64D0F113-A547-4DE3-AF3E-4AED2867C4D9Q36979441-B56272B6-C95E-439D-9DD6-1ABDFCF59A86Q36992262-D4320CDC-EFD9-4C57-8270-A04E35190890Q37238101-F5A416C5-CAAF-41C0-A6B2-750D104D195BQ37384669-8561D4BA-5A0C-4721-A363-F57FA4AAA67AQ37708174-6479E9BB-6244-45FD-B62A-28BC16513F9CQ38220044-95107248-0102-4ED7-AD47-F7521DAF8C6BQ38220183-DC8594BD-31AB-4590-84F3-5D9BCACF2634Q39944693-FB691D87-EB68-4960-811C-F86D9763C894Q40296418-75BB2F12-D800-4A76-A23B-A1D2267116E0Q45289470-1DB0E41E-A8D8-41CB-9389-C13B26A80A61Q45362313-7180C6A6-9362-4412-878E-7B3070CDF587Q47887267-333A7637-32B6-4A98-B574-A80E56C57029Q48443870-E1CEDF26-C0A6-4D2F-855C-177AB8B9CB20Q52689045-9D5EFB01-9662-446C-8D24-6945DF231229Q53397232-2705631E-8E9F-4FAE-84B2-E7A475DD83F9
P2860
Impact of screening on incidence and mortality of prostate cancer in the United States.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Impact of screening on incidence and mortality of prostate cancer in the United States.
@ast
Impact of screening on incidence and mortality of prostate cancer in the United States.
@en
Impact of screening on incidence and mortality of prostate cancer in the United States.
@nl
type
label
Impact of screening on incidence and mortality of prostate cancer in the United States.
@ast
Impact of screening on incidence and mortality of prostate cancer in the United States.
@en
Impact of screening on incidence and mortality of prostate cancer in the United States.
@nl
prefLabel
Impact of screening on incidence and mortality of prostate cancer in the United States.
@ast
Impact of screening on incidence and mortality of prostate cancer in the United States.
@en
Impact of screening on incidence and mortality of prostate cancer in the United States.
@nl
P2093
P1476
Impact of screening on incidence and mortality of prostate cancer in the United States.
@en
P2093
P304
P356
10.1093/OXFORDJOURNALS.EPIREV.A000787
P577
2001-01-01T00:00:00Z